AbbVie-Allergan Merger Gets Final Clearance in Europe

The European Commission has approved the divestiture of Allergan’s brazikumab to AstraZeneca, paving the way for Allergan’s $63 billion acquisition by AbbVie.

The commission required Allergan to sell off its investigational drug, an IL-23 inhibitor candidate for Crohn’s disease and ulcerative colitis, because the merger could disrupt development of the innovative treatment.

The two companies said they are expecting a decision on the merger by the Federal Trade Commission early in the second quarter of 2020.